May 20, 2026

How to Test for Lyme Disease: 4 Tests and What Each Reveals

The CDC two-tier testing standard, plus what ELISA, Western blot, PCR, and modified two-tier EIA-EIA testing each detect. Includes why early Lyme often tests negative, common false positives, co-infections worth screening for, and a clear decision tree for when to test versus when to start treatment empirically.

Quick Summary

Standard Lyme disease testing follows a two-tier approach recommended by the CDC. First, an ELISA or EIA antibody screen. If positive or equivocal, a confirmatory Western blot. PCR molecular testing is used in specific scenarios like joint fluid analysis or early infection when antibodies have not developed yet. The biggest pitfall is testing too early: antibodies take 2 to 4 weeks to develop, so a test in the first 1 to 2 weeks after a tick bite is often falsely negative even with active infection. If you have a documented tick bite and the classic bullseye rash, current guidelines recommend starting antibiotic treatment without waiting for test results.

You were outdoors. A few weeks later you have flu-like symptoms, joint pain, maybe a rash you cannot quite remember, and you are wondering if it could be Lyme. You ask your doctor, who orders a blood test. Three weeks pass and the result is “indeterminate.” Now what?

Here is the problem with Lyme testing in 2026. The standard tests are antibody-based, which means they detect your immune response to the bacteria rather than the bacteria itself. That works well after 4 to 6 weeks of infection when antibodies have built up, but it works poorly in the first 1 to 3 weeks when the highest cure rates from early treatment are still possible. The test that catches early infection (PCR) is not routinely used because it is less sensitive in blood, and the test that catches late or chronic infection (Western blot) has known false-positive issues.

This guide explains exactly what each Lyme test measures, when each one is the right choice, why timing matters more than which test you pick, what to do if your result is ambiguous, and which co-infections from the same tick bite are worth screening for at the same time.

When to Get Tested for Lyme

Testing makes sense if you have one or more of:

• A known recent tick bite (within the last 6 weeks) and any new symptoms
• An expanding red rash, especially with central clearing (erythema migrans)
• Recent travel to a Lyme-endemic region (Northeast US, Upper Midwest, Northern California, parts of Europe and Asia) plus unexplained flu-like illness
• Unexplained joint pain, particularly knees, that started after potential tick exposure
• Bell palsy (facial paralysis) or other neurological symptoms with possible tick exposure
• Atrioventricular heart block or new arrhythmia with possible tick exposure
• Chronic unexplained symptoms (fatigue, brain fog, joint pain) that started after an outdoor exposure

Testing is generally not useful for:

• Routine screening in an asymptomatic person with no exposure history
• Re-testing within the first 3 weeks after a treated infection (antibodies persist for months to years and do not indicate active infection)
• Confirming “chronic Lyme” diagnoses in the absence of objective signs (this is a contested clinical area)

A 2025 review in Annals of Internal Medicine emphasized that the diagnosis of Lyme disease is primarily clinical, supported by laboratory testing, not driven by it [1].

The CDC Two-Tier Testing Standard

The CDC has recommended a two-step testing algorithm since 1995. The logic is straightforward: use a sensitive screening test first to catch all possible infections, then use a more specific confirmatory test to filter out false positives.

Step 1: ELISA or EIA (Enzyme Immunoassay)

The first-tier test is an ELISA (or its newer variant, EIA), which detects total IgM and IgG antibodies against Borrelia burgdorferi (the bacterium that causes Lyme disease in the US) or related species in Europe.

How it works:

• Your blood serum is exposed to Borrelia antigens fixed to a plate
• If you have antibodies, they bind to the antigens
• A detection reagent flags the bound antibodies
• The intensity of the signal is reported as a numeric result with a positivity threshold

Strengths:

• Highly sensitive (catches most true infections by week 4-6)
• Cheap, fast, automated, widely available
• Suitable for initial screening

Limitations:

• Lower specificity than the confirmatory test (false positives possible)
• Often negative in the first 1-3 weeks of infection before antibodies develop
• Can remain positive for months to years after successful treatment, so it does not distinguish active from past infection

If the ELISA is positive or equivocal, proceed to step 2. If the ELISA is negative in someone with high pretest probability (recent tick bite + classic rash), repeat in 2-4 weeks because seroconversion may not have occurred yet.

Step 2: Western Blot

The confirmatory test is a Western blot, which separately detects IgM and IgG antibodies against multiple specific Borrelia proteins. This higher resolution helps distinguish true Lyme infection from cross-reactive antibodies (e.g., from other infections or autoimmune conditions).

How it works:

• Borrelia proteins are separated by molecular weight on a gel
• Your serum is added; antibodies bind to specific protein bands
• The pattern of bands (IgM and IgG separately) is read

CDC interpretation criteria for a positive Western blot:

• IgM positive: at least 2 of 3 specific bands (24, 39, 41 kDa), but only counts if within 30 days of symptom onset
• IgG positive: at least 5 of 10 specific bands

A 2016 study in The Journal of Pediatrics found that IgM Western blots have meaningfully high false-positive rates in low-prevalence populations and should be interpreted cautiously [2]. A 2020 study in the Journal of the Pediatric Infectious Diseases Society confirmed that two-tier results can vary significantly depending on which laboratory runs the test [3].

The bottom line:

• IgM positive + symptoms < 30 days = early Lyme is likely
• IgG positive (any timeframe) = past or current Lyme exposure
• IgG negative + IgM positive + symptoms > 30 days = consider false positive

Step 2 Alternative: Modified Two-Tier (EIA + EIA)

In 2019, the CDC accepted a newer modified two-tier algorithm using two ELISAs instead of ELISA + Western blot. This simplification is faster, fully automated, and shows similar overall sensitivity and specificity to the traditional two-tier approach.

Most large clinical labs now offer both options. Modified two-tier is gradually becoming the default.

Test 3: PCR (Molecular / DNA Detection)

PCR amplifies and detects Borrelia DNA directly, which means it can detect active infection rather than the immune response to it.

Strengths:

• Can detect very early infection (before antibodies develop)
• Specific to the bacteria itself, not your immune response

Limitations:

• Low sensitivity in blood (Borrelia is rarely in the bloodstream in detectable amounts)
• Higher sensitivity in joint fluid, cerebrospinal fluid, or skin biopsy
• Expensive, not always covered by insurance, requires specialized lab

Where PCR is genuinely useful:

• Joint fluid in suspected Lyme arthritis
• CSF in suspected Lyme neuroborreliosis
• Skin biopsy of an erythema migrans rash when serology is still negative
• Synovial fluid in monoarticular knee arthritis with possible Lyme

A 2020 study in PLoS One demonstrated that newer molecular diagnostic assays for Borrelia DNA detection are increasing in sensitivity but still complementary to (not replacement for) serology [4].

For routine outpatient Lyme suspicion, PCR is not typically the right starting test.

Test 4: T-Cell-Based Tests (Newer, Investigational)

Several newer tests measure T-cell activation in response to Borrelia antigens, similar in concept to interferon-gamma release assays for tuberculosis. The evidence is still emerging and these tests are not yet part of standard CDC recommendations.

If your conventional testing is repeatedly inconclusive but your clinical picture strongly suggests Lyme, discuss whether a research-grade T-cell test is appropriate with an infectious disease specialist.

Why Early Lyme Often Tests Negative

This is the single most important fact about Lyme testing. Standard antibody tests are unreliable in the first 1 to 3 weeks of infection because your immune system has not yet produced enough detectable antibodies.

Antibody timeline after infection:

• Week 1: usually negative (< 30% sensitivity)
• Week 2: variable (40 to 60% sensitivity)
• Week 3-4: improving (70 to 80% sensitivity)
• Week 6 and beyond: high sensitivity (> 90% for true infection)

The practical implication: if you have a confirmed tick bite and the classic bullseye rash (erythema migrans), current guidelines say to treat without testing. The clinical picture is diagnostic. A negative test in this window does not rule out Lyme, and waiting for testing delays treatment during the window when cure rates are highest.

A 2016 Nature Reviews Disease Primers review confirmed that erythema migrans is sufficient for clinical diagnosis without laboratory confirmation in endemic areas [5].

False Positives and False Negatives

Common Causes of False-Positive Lyme Tests

• Infectious mononucleosis (EBV): cross-reactive antibodies
• Syphilis: Treponema is related to Borrelia
• Other tick-borne diseases (anaplasmosis, ehrlichiosis): co-infection or cross-reactivity
• Autoimmune conditions (lupus, rheumatoid arthritis)
• Recent viral illness in general

A 2016 J Pediatrics study found that IgM false positives were particularly common in pediatric populations and warned against single-positive-band interpretation [2].

Common Causes of False-Negative Lyme Tests

• Testing too early (within 3 weeks of exposure)
• Immunocompromise (HIV, immunosuppressive therapy, chemotherapy)
• Prior antibiotic exposure that aborted the immune response
• Geographic variation: Borrelia species in Europe (B. afzelii, B. garinii) may not react well to US-targeted assays designed for B. burgdorferi

A 2005 Clinical Microbiology Reviews paper that remains a key reference noted that late-stage Lyme can also test negative if the IgM has waned and IgG is read at the threshold of detectability [6].

Co-Infections to Consider

Ticks that carry Borrelia often carry other pathogens. If you are testing for Lyme, consider testing for these at the same time, especially with severe or atypical presentation:

• Babesia (Babesiosis): malaria-like illness, fever, hemolysis, can be life-threatening
• Anaplasma phagocytophilum (Anaplasmosis): fever, headache, low white blood cell count
• Ehrlichia: similar to anaplasmosis
• Borrelia miyamotoi: Lyme-related but distinct relapsing fever spirochete
• Powassan virus: rare but serious encephalitis
• Bartonella: controversial co-infection, sometimes implicated in chronic symptoms

A 2025 review in Journal of Neurology covered the spectrum of tick-induced neurological disorders and emphasized the importance of co-infection consideration in severe presentations [7].

Post-Treatment Lyme Disease Syndrome (PTLDS)

About 10 to 20 percent of treated Lyme patients report persistent symptoms (fatigue, joint pain, cognitive difficulty) for more than 6 months after standard antibiotic treatment. This is called Post-Treatment Lyme Disease Syndrome (PTLDS).

A 2022 review in Clinical Reviews in Allergy and Immunology distinguished PTLDS (objectively documented prior infection plus persistent symptoms) from “chronic Lyme” (persistent symptoms without documented prior infection), and noted that PTLDS is a recognized clinical syndrome while chronic Lyme without documentation is controversial [8]. A 2025 guidelines paper in Infectious Diseases Now updated the recommended approach to PTLDS, emphasizing symptom management rather than prolonged antibiotic courses [9].

Testing in PTLDS is complicated: antibodies persist after treatment, so a positive serology does not confirm ongoing active infection. PCR on joint fluid or CSF may be useful in specific scenarios.

When to Get a Doctor Involved

Lyme disease testing is not a self-service interpretation exercise. See a physician (especially an infectious disease specialist in non-endemic areas) when you have:

• A confirmed tick bite plus any symptoms within 30 days
• A bullseye-shaped expanding rash (do not wait for testing)
• Neurological symptoms (facial paralysis, severe headache, memory changes)
• New cardiac symptoms (palpitations, dizziness, chest discomfort)
• Joint swelling, particularly in the knees
• Repeatedly equivocal or contradictory test results

A 2019 review in Current Opinion in Infectious Diseases covered the specific approach to Lyme neuroborreliosis, which requires CSF analysis rather than blood testing alone [10].

Test This with Mito

Mito Health offers a dedicated Lyme disease blood test alongside the broader biomarker panels that contextualize tick-borne illness symptoms:

• Lyme Disease Blood Test: blood-based screening for Borrelia exposure and tick-borne infections. The fastest way to check whether your symptoms could be tick-bite related. Available at $69 as a standalone test.
• Mito Core Panel: 100+ biomarkers including hsCRP (inflammation), liver enzymes, CBC with differential, and other markers that often shift in active infection. Useful when symptoms are unexplained and you want to rule out other causes alongside Lyme. Individual testing starts at $349, duo testing at $668.
• Build Your Own panel: select hsCRP, CBC, and liver enzymes à la carte for repeat tracking. Pricing starts at $40 per marker.
• How Mito testing works: walks through sample collection, turnaround, and how the physician-guided interpretation report is delivered.

How to decide which panel fits your situation:

• Recent tick bite (within 6 weeks) plus symptoms: Lyme Disease Blood Test. Direct screening for the most likely diagnosis. Test at 4 to 6 weeks post-bite for highest sensitivity if you test before symptoms.
• Unexplained chronic symptoms (fatigue, joint pain, brain fog) with possible past tick exposure: Mito Core Panel first to rule out other common causes (thyroid, autoimmune, metabolic), then Lyme testing if the panel is clean and Lyme remains plausible.
• Tracking inflammation response after antibiotic treatment: Build Your Own with hsCRP and CBC at baseline, 4 weeks into treatment, and 12 weeks post-treatment.

If you have a bullseye rash or a confirmed recent tick bite with new symptoms, see a physician immediately for treatment rather than waiting on testing.

Key Takeaways

• The standard Lyme test is a two-tier antibody approach: ELISA or EIA first, then Western blot (or a second EIA in the modified two-tier algorithm) for confirmation.
• Antibody tests are unreliable in the first 1 to 3 weeks of infection. If you have a tick bite and classic bullseye rash, treat first and test later.
• PCR detects bacterial DNA directly but has low sensitivity in blood. It is most useful in joint fluid, CSF, or skin biopsy.
• Western blot interpretation requires 2 of 3 specific IgM bands within 30 days of symptoms, OR 5 of 10 specific IgG bands at any time.
• Common false-positive causes: EBV, syphilis, other tick-borne diseases, autoimmune conditions.
• Common false-negative causes: testing too early, immunocompromise, geographic strain mismatch.
• Co-infections (Babesia, Anaplasma, Ehrlichia) are worth screening for in severe or atypical presentations.
• Post-treatment symptoms persisting beyond 6 months are recognized as PTLDS but do not necessarily indicate ongoing active infection.
• Lyme is fundamentally a clinical diagnosis supported by labs, not driven by them.

Medical Disclaimer

This guide is for educational purposes and does not replace evaluation by a qualified healthcare professional. Lyme disease can cause serious complications including neurological damage, cardiac involvement, and arthritis if untreated. If you have a confirmed tick bite, an expanding red rash, or new symptoms after potential tick exposure, see a physician promptly. Do not rely on direct-to-consumer testing alone for diagnosis or treatment decisions in suspected acute Lyme disease.

Track Your Progress

Lyme testing is most useful when interpreted alongside markers that reflect systemic inflammation and immune function:

• hsCRP for systemic inflammation that often elevates during active infection
• How to Improve Your hsCRP Naturally for the targeted inflammation-reduction protocol after treatment
• Understanding Autoimmune Markers for the autoimmune workup that often overlaps with chronic Lyme-like symptoms

Related Content

• Chronic Fatigue Symptoms, Dangers, and Treatment for the broader differential when fatigue is the dominant symptom

References

1. Lyme Disease. Ann Intern Med. 2025. PMID 40354663.
2. Seriburi V et al. False Positive Lyme Disease IgM Immunoblots in Children. J Pediatr. 2016. PMID 27157898.
3. Two-Tier Lyme Disease Serology Test Results Can Vary According to the Specific First-Tier Test Used. J Pediatric Infect Dis Soc. 2020. PMID 30793167.
4. Development of a sensitive molecular diagnostic assay for detecting Borrelia. PLoS One. 2020. PMID 33253179.
5. Steere AC et al. Lyme borreliosis. Nat Rev Dis Primers. 2016. PMID 27976670.
6. Aguero-Rosenfeld ME et al. Diagnosis of lyme borreliosis. Clin Microbiol Rev. 2005. PMID 16020686.
7. Tick-induced neurological disorders. J Neurol. 2025. PMID 40879811.
8. Bobe JR et al. A Review of Post-treatment Lyme Disease Syndrome and Chronic Lyme Disease for the Practicing Physician. Clin Rev Allergy Immunol. 2022. PMID 34687445.
9. Guidelines for Lyme borreliosis: post-treatment Lyme disease syndrome (PTLDS). Infect Dis Now. 2025. PMID 41314472.
10. Halperin JJ. Lyme neuroborreliosis. Curr Opin Infect Dis. 2019. PMID 30921086.